The disclosure comes as another of Arcus's TIGIT trials flops.
ApexOnco Front Page
Recent articles
Lilly makes its second in vivo Car-T acquisition, buying the privately held Kelonia for $3.25bn.
Roche curbs its TIGIT push, while a co-stimulation crunch could be bad news for Regeneron.
An adcom on Imfinzi’s Aegean trial will show whether neoadjuvant and adjuvant benefits must be split out.
Soon after filing to float in Hong Kong, Baili takes HER2 and DLL3-targeting ADCs into the clinic.
ASP3082 grabs some early attention among degraders set to feature at ESMO.
The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.
Early attention falls on ADCs originated by ProfoundBio, SystImmune, MediLink and Seagen.